TCGA-34-8454-01A-11R-2326-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 62
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.510
- INTERFERON_ALPHA_RESPONSE+0.500
- E2F_TARGETS+0.490
- INTERFERON_GAMMA_RESPONSE+0.480
- IL6_JAK_STAT3_SIGNALING+0.450
- ALLOGRAFT_REJECTION+0.410
- INFLAMMATORY_RESPONSE+0.390
- TNFA_SIGNALING_VIA_NFKB+0.390
- MITOTIC_SPINDLE+0.350
- TGF_BETA_SIGNALING+0.340
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.300
- OXIDATIVE_PHOSPHORYLATION-0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.150
- GLYCOLYSIS-0.140
- PROTEIN_SECRETION-0.090
- KRAS_SIGNALING_DN-0.070
- SPERMATOGENESIS-0.070
- FATTY_ACID_METABOLISM+0.000
- HYPOXIA+0.000
- UV_RESPONSE_UP+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | F547C7BB-DBF1-4805-A0EA-D8BC36606032 | — | — | 0.895 |
| 2 | TCGA-39-5030-01A-01R-1443-07 | — | cohortSQ1 | 0.867 |
| 3 | TCGA-CQ-5334-01A-01R-1686-07 | — | — | 0.858 |
| 4 | MNG736 | — | — | 0.851 |
| 5 | 25B5E54F-5858-454C-9B23-440A82450912 | — | — | 0.848 |
| 6 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.844 |
| 7 | SRR934943 | — | — | 0.836 |
| 8 | 33233781-A799-4610-86FC-C836713D31AA | — | — | 0.831 |
| 9 | SRR934753 | — | — | 0.830 |
| 10 | SRR934737 | — | — | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.270 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.190 | Inavolisib | — uncovered |